Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 4
1978 1
1979 1
1980 1
1981 2
1982 2
1983 1
1984 1
1985 5
1986 3
1987 6
1988 6
1989 4
1990 5
1991 1
1992 2
1993 5
1994 2
1995 7
1996 6
1997 5
1998 6
1999 5
2000 1
2001 7
2002 8
2003 2
2004 4
2005 3
2006 4
2007 3
2008 1
2009 4
2010 5
2011 8
2012 4
2013 6
2014 4
2015 3
2016 5
2017 2
2018 2
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Robertson JFR, et al. Among authors: panasci l. Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29. Lancet. 2016. PMID: 27908454 Clinical Trial.
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM, Maritan SM, Quaiattini A, Darlix A, Ratosa I, Ferraro E, Griguolo G, Guarneri V, Pellerino A, Hofer S, Jacot W, Stemmler HJ, van den Broek MPH, Dobnikar N, Panet F, Lahijanian Z, Morikawa A, Seidman AD, Soffietti R, Panasci L, Petrecca K, Rose AAN, Bouganim N, Dankner M. Lazaratos AM, et al. Among authors: panasci l. Breast. 2023 Jun;69:451-468. doi: 10.1016/j.breast.2023.04.008. Epub 2023 May 1. Breast. 2023. PMID: 37156650 Free PMC article.
PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin.
Sharif-Askari B, Panasci L, Aloyz R. Sharif-Askari B, et al. Among authors: panasci l. Front Biosci (Landmark Ed). 2023 Mar 16;28(3):52. doi: 10.31083/j.fbl2803052. Front Biosci (Landmark Ed). 2023. PMID: 37005765 Free article.
Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Aloyz R, et al. Among authors: panasci l. Leukemia. 2004 Mar;18(3):409-14. doi: 10.1038/sj.leu.2403247. Leukemia. 2004. PMID: 14712290
Pharmacological targeting of eIF4E in primary CLL lymphocytes.
Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R. Martinez-Marignac V, et al. Among authors: panasci l. Blood Cancer J. 2013 Sep 13;3(9):e146. doi: 10.1038/bcj.2013.43. Blood Cancer J. 2013. PMID: 24036945 Free PMC article. No abstract available.
156 results